Ambivalent Effects of Atorvastatin on Angiogenesis, Epidermal Cell Proliferation and Tumorgenesis in Animal Models

Garjani, Alireza; Rezazadeh, Hassan; Andalib, Sina; Ziaee, Mojtaba; Doustar, Yousef; Soraya, Hamid; Garjani, Mehraveh; Khorrami, Arash; Asadpoor, Mostafa; Maleki‐Dizaji, Nasrin

doi:10.6091/ibj.1017.2012

Cited by 6 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been showed that statins stimulate angiogenesis, which is regarded as a potential approach in the treatment of coronary artery disease [ 6 ]. In contrast, another study has demonstrated that atorvastatin impairs the myocardial angiogenic response to chronic ischemia [ 7 ], or even interrupts angiogenesis [ 8 ]. Furthermore, it has been suggested that statins may affect the process of angiogenesis biphasic, depending on the administered doses [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes

et al. 2021

View full text Add to dashboard Cite

The aim of this study was to investigate the influence of statins on the secretion of angiogenesis mediators by the peripheral blood mononuclear cells (PBMCs) derived from patients suffering from type 2 diabetes. The study group comprised 30 participants and included: 10 statin-treated patients with diabetes, 10 statin-free diabetic subjects, and 10 statin-free non-diabetic individuals. PBMCs isolated from the blood were cultured in vitro in standard conditions and in an environment mimicking hyperglycemia. Culture supernatants were evaluated for VEGF, MCP-1, Il-10, and Il-12 by flow cytometry using commercial BDTM. Cytometric Bead Array tests. The secretion of VEGF, MCP-1 and Il-12 by PBMCs, cultured both in standard and hyperglycemic conditions, was significantly lower in the statin-treated patients with type 2 diabetes in comparison with the statin-free diabetic patients. Conversely, the secretion of Il-10 was higher in the statin-treated than in the statin-free diabetic patients. VEGF, MCP-1 and Il-12 levels in PBMCs supernatants from the glucose-containing medium were higher than those from the standard medium in each of the diabetic groups. The results of the study suggest that statins in low doses exhibit an antiangiogenic activity, reducing the secretion of potent proangiogenic factors, such as VEGF and MCP-1, and increasing the secretion of antiangiogenic Il-10 by PBMCs, also under hyperglycemic conditions characteristic for type 2 diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes

et al. 2021

View full text Add to dashboard Cite

show abstract

Survival of the hospitalized patients with COVID‐19 receiving atorvastatin: A randomized clinical trial

Ghafoori

Saadati

Taghavi

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

As statins decrease the progression of sepsis and its related mortality, this study aimed to evaluate the effect of atorvastatin on survival and symptom improvement in hospitalized patients with COVID‐19. This randomized controlled trial was performed on 156 hospitalized patients with COVID‐19 in Bojnourd city in 2021. Patients were randomly divided into comparison (standard therapy: hydroxychloroquine + Kaletra®) and intervention groups (atorvastatin 20 mg, SD, plus standard therapy). The main outcomes were the rate of symptom improvement, duration of hospitalization, need for intubation, and mortality rate. In this study, seven patients died, two patients (2.6%) in the comparison group and five (6.6%) in the intervention group. The mean hospitalization days ( p = 0.001), the pulse rate ( p = 0.004), and the frequency of hospitalization in the ICU ward (18.4% vs. 1.3%) were longer and greater in the intervention group. The remission probability in the comparison group was greater ( p = 0.0001). The median hospitalization days in the intervention group was longer ( p < 0.001) and remission in the comparison group occurred 1.71 times sooner (hazard ratio = 1.70, 95% confidence interval = 1.22–2.38, p = 0.002). Totally, adding atorvastatin to the standard regime in this study increased hospitalization days and imposed negative effects on symptom improvement in hospitalized patients with COVID‐19.

show abstract

In vivo antioxidant and kidney protective potential of Atorvastatin against cadmium chloride-induced kidney injury in male Wistar rat

et al. 2022

View full text Add to dashboard Cite

Ambivalent Effects of Atorvastatin on Angiogenesis, Epidermal Cell Proliferation and Tumorgenesis in Animal Models

Cited by 6 publications

References 27 publications

Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes

Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes

Survival of the hospitalized patients with COVID‐19 receiving atorvastatin: A randomized clinical trial

In vivo antioxidant and kidney protective potential of Atorvastatin against cadmium chloride-induced kidney injury in male Wistar rat

Contact Info

Product

Resources

About